Abstract
Objective: This study observes patients with acute coronary syndromes. To the diagnosis of acute myocardial infarction (AIM) we use the new proteins biochip technologies.
The aim of this study is to evaluate the new strategy of laboratory diagnostic method and to confront the less known's cardio markers with the standard markers and with the clinical parameters. Material and methods: This study contains 44 patients with AIM and the blood samples were taken in the time of the admission, 24 hours later and then the fourth or fifth day of hospitalization.
We tested the cardiac panel Cardiac Array (cTnI, CK MB, myoglobin, CAIII, FABP and GPBB) on the biochip analyser The Evidence Investigator TM from Randox (Randox Laboratories Ltd., United Kingdom). Results: Our study confirms the close relationship between FABP and GPBB to AIM and we can consider these markers as early markers in the diagnosis of AIM.
FABP has, as the standard markers CKMB or TnI, the prognostic value too (the higher values are associated with he systolic dysfunction). This study employs a new strategy of the biochip analyser in the diagnosis of AIM (in the same time we have the concentrations of more parameters and complex information about AIM).
Conclusion: This method presents new interesting multianalytes approach to the diagnosis of the AIM. But this method requires a lot of further studies to verify this technology.